Trial Profile
A Prospective Phase I and II Trial of Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Dec 2020
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Nov 2020 Status changed from recruiting to discontinued.
- 30 May 2019 Status changed from not yet recruiting to recruiting.
- 12 Apr 2019 Planned End Date changed from 31 Mar 2022 to 30 Jun 2022.